{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:14:13Z","timestamp":1788952453144,"version":"build-2803163510"},"reference-count":191,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Migraine is a prevalent, complex, and disabling neurological disorder. Available treatments consist of repurposed drugs, with medication switching and treatment failure a common occurrence. Pathophysiological models have shifted from migraine being a primarily vascular disorder to a complex network disease encompassing cortical, hypothalamic, thalamic, brainstem, trigeminovascular, and meningeal structures. These areas are interconnected by cascades of multiple signalling transmitters and hormones. This review explores how these molecules may offer novel pharmacological targets for efficacious treatments tailored to the pathophysiology of migraine. Calcitonin gene-related peptide (CGRP) directed therapies include antagonists (\u201cgepants\u201d) and monoclonal antibodies. Both drug classes have shown promising effects in managing pain in acute migraine attacks and in prophylactically reducing headache frequency, even within treatment-resistant migraine populations. Animal studies have shown drugs targeting pituitary adenylate cyclase-activating polypeptide (PACAP) signalling to reduce meningeal vasodilation and chronic allodynia. PACAP ligand-directed monoclonal antibodies offer therapeutic promise in patients with treatment-resistant migraine; however, this evidence base is limited and requires further research. Amylin may offer a novel therapeutic target for migraine; however, currently no such therapies have been developed. Neurokinin receptor antagonists have so far shown little promise in clinical trials, further challenging the role of substance p and neurogenic inflammation in migraine pathophysiology. Building upon the success of triptan therapy, novel serotonergic medications such as 5-HT\n                    <jats:sub>1F<\/jats:sub>\n                    agonists (\u2018ditans\u2019) have shown positive benefit in clinical studies as an alternative treatment to triptans. Additional emerging molecular targets include K\n                    <jats:sub>ir<\/jats:sub>\n                    6.1\/SUR2B K\n                    <jats:sub>ATP<\/jats:sub>\n                    and K\n                    <jats:sub>v<\/jats:sub>\n                    7 potassium channels, together with GluK1 and mGluR5 glutamate receptors. In contrast, despite a strong mechanistic rationale, therapeutic strategies targeting orexinergic pathways, nitric oxide synthase, and phosphodiesterase\/cyclic nucleotide signalling have yet to demonstrate clinical efficacy in migraine. Overall, CGRP, PACAP, and serotonergic signalling offer the greatest promise as emerging pharmacological targets for migraine therapy. Most other emerging pathways remain in early, preclinical stages, with further research needed to bridge the gap between pathophysiological plausibility and robust clinical translation.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2026.1924544","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:34:54Z","timestamp":1788950094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging pharmacological targets in migraine therapy: CGRP and beyond"],"prefix":"10.3389","volume":"17","author":[{"given":"D.","family":"Atraszkiewicz","sequence":"first","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust","place":["Leeds, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dahiya","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust","place":["Leeds, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1212\/WNL.0b013e3182824e66","article-title":"A randomized controlled trial of intranasal ketamine in migraine with prolonged aura","volume":"80","author":"Afridi","year":"2013","journal-title":"Neurology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5214\/ans.0972.7531.12190210","article-title":"Serotonin and CGRP in migraine","volume":"19","author":"Aggarwal","year":"2012","journal-title":"Ann. Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/nejmoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"308ra157","DOI":"10.1126\/scitranslmed.aaa7557","article-title":"Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine","volume":"7","author":"Akerman","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/wco.0000000000000932","article-title":"Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine","volume":"34","author":"Al-Hassany","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/ph16030438","article-title":"Involvement of potassium channel signalling in migraine pathophysiology","volume":"16","author":"Al-Karagholi","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-017-0800-8","article-title":"The KATP channel in migraine pathophysiology: a novel therapeutic target for migraine","volume":"18","author":"Al-Karagholi","year":"2017","journal-title":"J. Headache Pain"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1177\/0333102420949863","article-title":"Effect of KATP channel blocker glibenclamide on levcromakalim-induced headache","volume":"40","author":"Al-Karagholi","year":"2020","journal-title":"Cephalalgia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1093\/brain\/awab136","article-title":"Opening of ATP sensitive potassium channels causes migraine attacks with aura","volume":"144","author":"Al-Karagholi","year":"","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1097\/j.pain.0000000000002238","article-title":"Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine","volume":"162","author":"Al-Karagholi","year":"","journal-title":"Pain"},{"key":"B11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-025-02022-2","article-title":"PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial","volume":"26","author":"Al-Karagholi","year":"2025","journal-title":"J. Headache Pain"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-024-01762-x","article-title":"Effects of PDE-3 inhibition in persistent post-traumatic headache: evidence of cAMP-dependent signaling","volume":"25","author":"Al-Khazali","year":"2024","journal-title":"J. Headache Pain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3331024251336132","DOI":"10.1177\/03331024251336132","article-title":"Effects of substance P on headache induction and arterial dilation in healthy adults","volume":"45","author":"Al-Khazali","year":"2025","journal-title":"Cephalalgia"},{"key":"B14","article-title":"Substance P triggers migraine attacks without aura: a randomised, double-blind, placebo-controlled, two-way crossover human experimental study","author":"Al-Khazali","year":"","journal-title":"Lancet (Preprints)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3331024261419409","DOI":"10.1177\/03331024261419409","article-title":"Hypersensitivity to phosphodiesterase-5 inhibition in post-traumatic headache: evidence of cGMP-dependent signaling","volume":"46","author":"Al-Khazali","year":"","journal-title":"Cephalalgia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3331024251355944","DOI":"10.1177\/03331024251355944","article-title":"Substance P and the trigeminovascular system: from preclinical mechanisms to human headache induction","volume":"45","author":"Alpay","year":"2025","journal-title":"Cephalalgia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6306","DOI":"10.1097\/js9.0000000000001480","article-title":"Surgical interventions for intractable migraine: a systematic review and meta-analysis","volume":"110","author":"Alrahbeni","year":"2024","journal-title":"Int. J. Surg."},{"key":"B18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40120-024-00586-w","article-title":"Safety and tolerability of combining CGRP monoclonal antibodies with gepants in patients with migraine: a retrospective study","volume":"13","author":"Alsaadi","year":"2024","journal-title":"Neurol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1177\/0333102417729113","article-title":"Altered thalamic connectivity during spontaneous attacks of migraine without aura: a resting-state fMRI study","volume":"38","author":"Amin","year":"2018","journal-title":"Cephalalgia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/01.j.pain.0000460325.25762.c0","article-title":"Modulation of nociceptive dural input to the trigeminocervical complex through GluK1 kainate receptors","volume":"156","author":"Andreou","year":"2015","journal-title":"Pain"},{"key":"B21","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10194-012-0479-9","article-title":"Depression and risk of transformation of episodic to chronic migraine","volume":"13","author":"Ashina","year":"2012","journal-title":"J. Headache Pain"},{"key":"B22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0333102420970889","article-title":"A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1056\/nejmoa2314577","article-title":"A monoclonal antibody to PACAP for migraine prevention","volume":"391","author":"Ashina","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3331024251398390","DOI":"10.1177\/03331024251398390","article-title":"Greater occipital nerve block for the treatment of migraine: an umbrella review, systematic review, and meta-analysis","volume":"45","author":"Atraszkiewicz","year":"2025","journal-title":"Cephalalgia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/20494637211014544","article-title":"The efficacy of botulinum toxin type-A for intractable chronic migraine patients with no pain-free time","volume":"16","author":"Atraszkiewicz","year":"2022","journal-title":"Br. J. Pain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/ncn3.12551","article-title":"The processes underlying chronic migraine pathophysiology and its treatment with botulinum toxin type A","volume":"9","author":"Atraszkiewicz","year":"2021","journal-title":"Neurol. Clin. Neurosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.pain.2004.02.005","article-title":"Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area","volume":"109","author":"Bartsch","year":"2004","journal-title":"Pain"},{"key":"B28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1139\/y95-120","article-title":"Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache","volume":"73","author":"Beattie","year":"1995","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.64719\/pb.4388","article-title":"Lasmiditan for the treatment of migraines with or without aura in adults","volume":"50","author":"Berger","year":"2020","journal-title":"Psychopharmacol. Bull."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1111\/head.13930","article-title":"Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine","volume":"60","author":"Berman","year":"2020","journal-title":"Headache"},{"key":"B31","doi-asserted-by":"publisher","first-page":"105950","DOI":"10.1016\/j.isci.2023.105950","article-title":"PACAP-PAC1 receptor inhibition is effective in opioid induced hyperalgesia and medication overuse headache models","volume":"26","author":"Bertels","year":"2023","journal-title":"iScience"},{"key":"B32","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1212\/01.wnl.0000225052.35019.f9","article-title":"Obesity is a risk factor for transformed migraine but not chronic tension-type headache","volume":"67","author":"Bigal","year":"2006","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/head.14433","article-title":"Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine","volume":"63","author":"Blumenfeld","year":"2023","journal-title":"Headache"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e085564","DOI":"10.1136\/bmj-2025-085564","article-title":"New treatments for migraine: CGRP monoclonal antibodies, gepants, and ditans","volume":"390","author":"Burch","year":"2025","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol. Clin."},{"key":"B36","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1526-4610.2011.02046.x","article-title":"Headache impact of chronic and episodic migraine: results from the American migraine prevalence and prevention study","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"key":"B38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0333102414544979","article-title":"Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/toxins18010033","article-title":"Botulinum toxin type A for the prevention of migraines: an umbrella review of systematic reviews","volume":"18","author":"Chamani","year":"2026","journal-title":"Toxins (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1476-5381.2010.00733.x","article-title":"Effects of ionotropic glutamate receptor antagonists on rat dural artery diameter in an intravital microscopy model","volume":"160","author":"Chan","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"},{"key":"B42","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/head.14062","article-title":"Real-world efficacy, tolerability, and safety of ubrogepant","volume":"61","author":"Chiang","year":"2021","journal-title":"Headache"},{"key":"B43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1046\/j.1468-1331.2000.00094.x","article-title":"Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency","volume":"7","author":"Christiansen","year":"2000","journal-title":"Eur. J. Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3331024231219475","DOI":"10.1177\/03331024231219475","article-title":"The shortcoming of using glibenclamide in exploratory clinical headache provocation studies","volume":"43","author":"Christophersen","year":"2023","journal-title":"Cephalalgia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/wnl.53.7.1473","article-title":"Increased brain serotonin synthesis in migraine","volume":"53","author":"Chugani","year":"1999","journal-title":"Neurology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1177\/03331024221114773","article-title":"The effects of certain TRP channels and voltage-gated KCNQ\/Kv7 channel opener retigabine on calcitonin gene-related peptide release in the trigeminovascular system","volume":"42","author":"Citak","year":"2022","journal-title":"Cephalalgia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/cells11152406","article-title":"ATP-sensitive potassium channels in migraine: translational findings and therapeutic potential","volume":"11","author":"Clement","year":"2022","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1093\/pm\/pnab093","article-title":"Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as Add-on therapy to OnabotulinumtoxinA in patients with chronic migraine","volume":"22","author":"Cohen","year":"2021","journal-title":"Pain Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00415-019-09571-y","article-title":"Increased neural connectivity between the hypothalamus and cortical resting-state functional networks in chronic migraine","volume":"267","author":"Coppola","year":"2020","journal-title":"J. Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"652136","DOI":"10.3389\/fphys.2021.652136","article-title":"The effect of K ATP channel blocker glibenclamide on CGRP-induced headache and hemodynamic in healthy volunteers","volume":"12","author":"Coskun","year":"2021","journal-title":"Front. Physiol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1468-2982.2009.01975.x","article-title":"Efficacy and safety of tonabersat, a gap-junction modulator, in the acute treatment of migraine: a double-blind, parallel-group, randomized study","volume":"29","author":"Dahl\u00f6f","year":"2009","journal-title":"Cephalalgia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/brain\/awq159","article-title":"Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers","volume":"133","author":"De Felice","year":"2010","journal-title":"Brain"},{"key":"B54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/0333102416640501","article-title":"Serotonergic mechanisms in the migraine brain - a systematic review","volume":"37","author":"Deen","year":"2017","journal-title":"Cephalalgia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.nicl.2018.01.016","article-title":"High brain serotonin levels in migraine between attacks: a 5-HT4 receptor binding PET study","volume":"18","author":"Deen","year":"2018","journal-title":"Neuroimage Clin."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1111\/j.1526-4610.2007.00776.x","article-title":"Hypothalamic activation in spontaneous migraine attacks","volume":"47","author":"Denuelle","year":"2007","journal-title":"Headache"},{"key":"B57","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","article-title":"Zavegepant: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"B58","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1526-4610.2006.00631.x","article-title":"Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American migraine prevalence and prevention study","volume":"47","author":"Diamond","year":"2007","journal-title":"Headache"},{"key":"B59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0333102410375725","article-title":"Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor","volume":"31","author":"Dieterle","year":"2011","journal-title":"Cephalalgia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1093\/brain\/awad261","article-title":"Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans","volume":"146","author":"Do","year":"2023","journal-title":"Brain"},{"key":"B61","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/sj.bjp.0703110","article-title":"Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist","volume":"129","author":"Doods","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/SAP.0000000000000063","article-title":"A systematic review of peripheral nerve interventional treatments for chronic headaches","volume":"72","author":"Ducic","year":"2014","journal-title":"Ann. Plast. Surg."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jpain.2013.03.010","article-title":"Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system","volume":"14","author":"Eftekhari","year":"2013","journal-title":"J. Pain"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e315","DOI":"10.1097\/sla.0000000000005057","article-title":"Efficacy and safety of migraine surgery: a systematic review and meta-analysis of outcomes and complication rates","volume":"275","author":"ElHawary","year":"2022","journal-title":"Ann. Surg."},{"key":"B65","doi-asserted-by":"publisher","first-page":"952","DOI":"10.5811\/westjem.2018.8.37875","article-title":"Low-dose ketamine does not improve migraine in the emergency department: a randomized placebo-controlled trial","volume":"19","author":"Etchison","year":"2018","journal-title":"West J. Emerg. Med."},{"key":"B66","unstructured":"Food and drug administration adverse events reporting system public dashboard\n          \n          \n          2026"},{"key":"B67","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/s0169-328x(98)00269-1","article-title":"Reduced nociceptive behavior in islet amyloid polypeptide (amylin) knockout mice","volume":"63","author":"Gebre-Medhin","year":"1998","journal-title":"Brain Res. Mol. Brain Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.regpep.2006.06.004","article-title":"Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist. AC187","volume":"137","author":"Gedulin","year":"2006","journal-title":"Regul. Pept."},{"key":"B69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0333102419864507","article-title":"PACAP27 induces migraine-like attacks in migraine patients","volume":"40","author":"Ghanizada","year":"2020","journal-title":"Cephalalgia"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Ann. Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0333102414566196","article-title":"Putting migraine to sleep: rexants as a preventive strategy","volume":"35","author":"Goadsby","year":"2015","journal-title":"Cephalalgia"},{"key":"B72","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3331024251325550","DOI":"10.1177\/03331024251325550","article-title":"International classification of headache disorders-4 - work in progress 2","volume":"45","author":"Goadsby","year":"2025","journal-title":"Cephalalgia"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.37765\/ajmc.2025.89822","article-title":"Cost-effectiveness analysis of ubrogepant, rimegepant, and zavegepant for acute migraine treatment vs usual care","volume":"31","author":"Gokhale","year":"2025","journal-title":"Am. J. Manag. Care"},{"key":"B75","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1046\/j.1468-2982.1997.1707785.x","article-title":"Ineffectiveness of Neurokinin-1 antagonist in acute migraine: a crossover study: a crossover study","volume":"17","author":"Goldstein","year":"1997","journal-title":"Cephalalgia"},{"key":"B76","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1046\/j.1468-2982.2001.00161.x","article-title":"Lanepitant, an NK-1 antagonist, in migraine prevention","volume":"21","author":"Goldstein","year":"","journal-title":"Cephalalgia"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/s0140-6736(01)06347-4","article-title":"Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial","volume":"358","author":"Goldstein","year":"","journal-title":"Lancet"},{"key":"B78","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s10194-022-01518-5","article-title":"The premonitory phase of migraine is due to hypothalamic dysfunction: revisiting the evidence","volume":"23","author":"Gollion","year":"2022","journal-title":"J. Headache Pain"},{"key":"B79","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/0333102413499648","article-title":"Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks","volume":"34","author":"Gomez-Mancilla","year":"2014","journal-title":"Cephalalgia"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/mSystems.00105-16","article-title":"Migraines are correlated with higher levels of nitrate-nitrite-and nitric oxide-reducing oral microbes in the American gut project cohort","volume":"1","author":"Gonzalez","year":"2016","journal-title":"mSystems"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/head.70057","article-title":"Evaluating dual calcitonin gene-related peptide antagonists for chronic migraine prevention","volume":"66","author":"Graves","year":"2026","journal-title":"Headache"},{"key":"B82","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s10194-026-02434-8","article-title":"Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention","volume":"27","author":"Guerzoni","year":"2026","journal-title":"J. Headache Pain"},{"key":"B83","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1093\/brain\/awu244","article-title":"Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase","volume":"137","author":"Guo","year":"2014","journal-title":"Brain"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1097\/j.pain.0000000000000702","article-title":"Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine","volume":"157","author":"Guo","year":"2016","journal-title":"Pain"},{"key":"B85","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1073\/pnas.071582498","article-title":"Mechanisms of migraine aura revealed by functional MRI in human visual cortex","volume":"98","author":"Hadjikhani","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B86","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1017\/s0317167100000123","article-title":"The biology of serotonin receptors: focus on migraine pathophysiology and treatment","volume":"26","author":"Hamel","year":"1999","journal-title":"Can. J. Neurol. Sci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S1474-4422(09)70135-8","article-title":"Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study","volume":"8","author":"Hauge","year":"2009","journal-title":"Lancet Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders","year":"2018","journal-title":"Cephalalgia"},{"key":"B89","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","article-title":"Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis","volume":"37","author":"Hepp","year":"2017","journal-title":"Cephalalgia"},{"key":"B90","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","article-title":"Evidence for orexinergic mechanisms in migraine","volume":"74","author":"Hoffmann","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1097\/j.pain.0000000000001858","article-title":"PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?","volume":"161","author":"Hoffmann","year":"2020","journal-title":"Pain"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1177\/0333102410370875","article-title":"Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache","volume":"30","author":"H\u00f8ivik","year":"2010","journal-title":"Cephalalgia"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1124\/jpet.105.090951","article-title":"Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception","volume":"315","author":"Holland","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1111\/j.1460-9568.2006.05168.x","article-title":"Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat","volume":"24","author":"Holland","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-018-0844-4","article-title":"PACAP in hypothalamic regulation of sleep and circadian rhythm: importance for headache","volume":"19","author":"Holland","year":"2018","journal-title":"J. Headache Pain"},{"key":"B96","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.sjpain.2012.08.002","article-title":"The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study","volume":"4","author":"Hougaard","year":"2013","journal-title":"Scand. J. Pain"},{"key":"B97","first-page":"358","article-title":"Peripheral nerve blocks for the treatment of headache disorders in the UK: an audit of BASH members\u2019 practice. IHC 2019 Late Breaking Abstracts","volume":"39","author":"Idrovo","year":"2019","journal-title":"Cephalalgia"},{"key":"B98","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/0333102420977106","article-title":"Interictal amylin levels in chronic migraine patients: a case-control study","volume":"41","author":"Irimia","year":"2021","journal-title":"Cephalalgia"},{"key":"B99","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0304-3959(89)90067-5","article-title":"Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics","volume":"38","author":"Iversen","year":"1989","journal-title":"Pain"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3331024251368757","DOI":"10.1177\/03331024251368757","article-title":"Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine","volume":"45","author":"Johnson","year":"2025","journal-title":"Cephalalgia"},{"key":"B101","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.npep.2016.11.004","article-title":"Anti-CGRP antibodies block CGRP-induced diarrhea in mice","volume":"64","author":"Kaiser","year":"2017","journal-title":"Neuropeptides"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e080107","DOI":"10.1136\/bmj-2024-080107","article-title":"Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis","volume":"386","author":"Karlsson","year":"2024","journal-title":"BMJ"},{"key":"B103","doi-asserted-by":"publisher","first-page":"823","DOI":"10.7326\/annals-25-02221","article-title":"Effectiveness and tolerability of pharmacologic prophylaxis for chronic migraine: a systematic review of randomized controlled trials","volume":"179","author":"Khalili","year":"","journal-title":"Ann. Intern Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3331024261441287","DOI":"10.1177\/03331024261441287","article-title":"Effectiveness and tolerability of pharmacological prophylaxis in migraine patients with prior preventive treatment failure: a systematic review and network meta-analysis of randomized controlled trials","volume":"46","author":"Khalili","year":"","journal-title":"Cephalalgia"},{"key":"B105","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40360-026-01140-0","article-title":"Efficacy and safety of rimegepant for acute and preventive treatment of migraine: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Khodeer","year":"2026","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1177\/03331024221080574","article-title":"Effect of KATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic","volume":"42","author":"Kokoti","year":"2022","journal-title":"Cephalalgia"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3331024241248211","DOI":"10.1177\/03331024241248211","article-title":"Non-vascular ATP-sensitive potassium channel activation does not trigger migraine attacks: a randomized clinical trial","volume":"44","author":"Kokoti","year":"2024","journal-title":"Cephalalgia"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3331024241281493","DOI":"10.1177\/03331024241281493","article-title":"A male-specific mechanism of meningeal nociceptor sensitization promoting migraine headache","volume":"44","author":"Kopruszinski","year":"2024","journal-title":"Cephalalgia"},{"key":"B109","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/brain\/awg009","article-title":"Migraine can be induced by sildenafil without changes in middle cerebral artery diameter","volume":"126","author":"Kruuse","year":"2003","journal-title":"Brain"},{"key":"B110","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1365-2567.2007.02705.x","article-title":"Neuropeptides activate human mast cell degranulation and chemokine production","volume":"123","author":"Kulka","year":"2008","journal-title":"Immunology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1136\/bmj.2.5705.327","article-title":"Comparative trial of serotonin antagonists in the management of migraine","volume":"2","author":"Lance","year":"1970","journal-title":"Br. Med. J."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1021\/jm030982t","article-title":"Structure\u2212Activity studies of orexin A and orexin B at the human orexin 1 and orexin 2 receptors led to orexin 2 receptor selective and orexin 1 receptor preferring ligands","volume":"47","author":"Lang","year":"2004","journal-title":"J. Med. Chem."},{"key":"B113","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s11916-013-0385-0","article-title":"Economic burden and costs of chronic migraine","volume":"18","author":"Lanteri-Minet","year":"2014","journal-title":"Curr. Pain Headache Rep."},{"key":"B114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1468-2982.1998.1801027.x","article-title":"Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks","volume":"18","author":"Lassen","year":"1998","journal-title":"Cephalalgia"},{"key":"B115","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0333102415620251","article-title":"Premonitory symptoms in migraine: a cross-sectional study in 2714 persons","volume":"36","author":"Laurell","year":"2016","journal-title":"Cephalalgia"},{"key":"B116","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1152\/jn.1944.7.6.359","article-title":"Spreading depression of activity in the cerebral cortex","volume":"7","author":"Le\u00e3o","year":"1944","journal-title":"J. Neurophysiol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","article-title":"A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life","volume":"20","author":"Leonardi","year":"2019","journal-title":"J. Headache Pain"},{"key":"B118","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1177\/0333102419833087","article-title":"Functional connectivity of hypothalamus in chronic migraine with medication overuse","volume":"39","author":"Lerebours","year":"2019","journal-title":"Cephalalgia"},{"key":"B119","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40120-023-00556-8","article-title":"Real-World use of ubrogepant as acute treatment for migraine with an anti-calcitonin gene-related peptide monoclonal antibody: results from COURAGE","volume":"13","author":"Lipton","year":"2024","journal-title":"Neurol. Ther."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/03331024221118929","article-title":"Efficacy of lasmiditan for the acute treatment of perimenstrual migraine","volume":"42","author":"MacGregor","year":"2022","journal-title":"Cephalalgia"},{"key":"B121","doi-asserted-by":"publisher","first-page":"13800","DOI":"10.1523\/JNEUROSCI.2154-15.2015","article-title":"Morphological abnormalities of thalamic subnuclei in migraine: a multicenter MRI study at 3 tesla","volume":"35","author":"Magon","year":"2015","journal-title":"J. Neurosci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-023-01622-0","article-title":"Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE study","volume":"24","author":"Manack Adams","year":"2023","journal-title":"J. Headache Pain"},{"key":"B123","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/brain\/awt320","article-title":"Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks","volume":"137","author":"Maniyar","year":"2014","journal-title":"Brain"},{"key":"B124","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s10194-019-0992-1","article-title":"Effects of monoclonal antagonist antibodies on calcitonin gene-related peptide receptor function and trafficking","volume":"20","author":"Manoukian","year":"2019","journal-title":"J. Headache Pain"},{"key":"B125","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10194-023-01574-5","article-title":"PAR2 activation in the dura causes acute behavioral responses and priming to glyceryl trinitrate in a mouse migraine model","volume":"24","author":"Mason","year":"2023","journal-title":"J. Headache Pain"},{"key":"B126","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/13543784.10.4.673","article-title":"Substance P receptor antagonists in the therapy of migraine","volume":"10","author":"May","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1177\/0333102419867280","article-title":"Hypothalamic regulation of headache and migraine","volume":"39","author":"May","year":"2019","journal-title":"Cephalalgia"},{"key":"B128","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/03331024211046618","article-title":"Clinical correlates of hypothalamic functional changes in migraine patients","volume":"42","author":"Messina","year":"2022","journal-title":"Cephalalgia"},{"key":"B129","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1177\/0333102420911623","article-title":"Altered regional cerebral blood flow and hypothalamic connectivity immediately prior to a migraine headache","volume":"40","author":"Meylakh","year":"2020","journal-title":"Cephalalgia"},{"key":"B130","doi-asserted-by":"publisher","first-page":"47","DOI":"10.33588\/rn.7802.2023176","article-title":"New therapeutic era for migraine attacks with recently approved monoclonal antibodies, ditans and gepants","volume":"78","author":"M\u00ednguez-Olaondo","year":"2024","journal-title":"Rev. Neurol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/s41582-023-00842-x","article-title":"The 5-HT1F receptor as the target of ditans in migraine: from bench to bedside","volume":"19","author":"Mitsikostas","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-025-02262-2","article-title":"Sildenafil provokes headache but not migraine in men with migraine without aura: a randomized, placebo-controlled crossover trial","volume":"27","author":"Mohammad","year":"2026","journal-title":"J. Headache Pain"},{"key":"B133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0031-6997(25)06663-3","article-title":"Nitric oxide: physiology, pathophysiology, and pharmacology","volume":"43","author":"Moncada","year":"1991","journal-title":"Pharmacol. Rev."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3331024231226186","DOI":"10.1177\/03331024231226186","article-title":"Pharmacologic characterization of atogepant: a potent and selective calcitonin gene-related peptide receptor antagonist","volume":"44","author":"Moore","year":"2024","journal-title":"Cephalalgia"},{"key":"B135","doi-asserted-by":"publisher","first-page":"e95508","DOI":"10.1371\/journal.pone.0095508","article-title":"Altered hypothalamic functional connectivity with autonomic circuits and the locus coeruleus in migraine","volume":"9","author":"Moulton","year":"2014","journal-title":"PLoS One"},{"key":"B136","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","article-title":"Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy","volume":"94","author":"Mullin","year":"2020","journal-title":"Neurology"},{"key":"B137","unstructured":"Atogepant for preventing migraine. Technology appraisal guidance TA973\n          \n          \n          2024"},{"key":"B138","unstructured":"Galcanezumab for preventing migraine. Technology appraisal guidance TA659\n          \n          \n          2020"},{"key":"B139","unstructured":"Rimegepant for preventing migraine. Technology appraisal guidance TA906"},{"key":"B140","unstructured":"Rimegepant for treating migraine. Technology appraisal guidance TA919"},{"key":"B141","unstructured":"Atogepant for treating migraine (ID6615). In development: GID-TA11817\n          \n          \n          2026"},{"key":"B142","unstructured":"Eptinezumab for preventing migraine. Technology appraisal guidance TA871"},{"key":"B143","unstructured":"Erenumab for preventing migraine. Technology appraisal guidance TA682\n          \n          \n          2021"},{"key":"B144","unstructured":"Fremanezumab for preventing migraine. Technology appraisal guidance TA764\n          \n          \n          2022"},{"key":"B145","unstructured":"Improved NHS migraine care to save thousands of hospital stays\n          \n          \n          2020"},{"key":"B146","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1177\/0333102413515345","article-title":"Phosphodiesterases 3 and 5 express activity in the trigeminal ganglion and co-localize with calcitonin gene-related peptide","volume":"34","author":"Nordgaard","year":"2014","journal-title":"Cephalalgia"},{"key":"B147","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/head.12732","article-title":"Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study","volume":"56","author":"Noruzzadeh","year":"2016","journal-title":"Headache"},{"key":"B148","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.pharmthera.2008.08.003","article-title":"The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache","volume":"120","author":"Olesen","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"B149","doi-asserted-by":"publisher","first-page":"2355571","DOI":"10.1080\/24740527.2024.2355571","article-title":"Pulsed radiofrequency neuromodulation of the greater occipital nerve for the treatment of headache disorders in adults: a systematic review","volume":"8","author":"Oliveira","year":"2024","journal-title":"Can. J. Pain"},{"key":"B150","first-page":"56","article-title":"Orexin-A levels in episodic and chronic migraine: implications for hypothalamic involvement?","volume":"33","author":"\u00d6zaydin","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3389\/fphar.2020.01240","article-title":"Antagonism of CGRP signaling by rimegepant at two receptors","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s10194-025-01959-8","article-title":"Revisiting substance P in migraine: a methodological approach inspired by anti-CGRP and anti-PACAP success","volume":"26","author":"Pellesi","year":"2025","journal-title":"J. Headache Pain"},{"key":"B153","doi-asserted-by":"publisher","first-page":"e2118543","DOI":"10.1001\/jamanetworkopen.2021.18543","article-title":"Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial","volume":"4","author":"Pellesi","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B154","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1468-2982.2004.00750.x","article-title":"Cerebrospinal fluid glutamate levels in chronic migraine","volume":"24","author":"Peres","year":"2004","journal-title":"Cephalalgia"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3331024241259489","DOI":"10.1177\/03331024241259489","article-title":"Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation","volume":"44","author":"Raffaelli","year":"2024","journal-title":"Cephalalgia"},{"key":"B156","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.neulet.2010.08.050","article-title":"Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats","volume":"484","author":"Ramachandran","year":"2010","journal-title":"Neurosci. Lett."},{"key":"B157","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.parkreldis.2014.05.003","article-title":"Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias","volume":"20","author":"Rascol","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1097\/j.pain.0000000000002537","article-title":"Automated detection of squint as a sensitive assay of sex-dependent calcitonin gene-related peptide and amylin-induced pain in mice","volume":"163","author":"Rea","year":"2022","journal-title":"Pain"},{"key":"B159","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0304-3940(98)00442-x","article-title":"Nitric oxide does not mediate cerebral blood flow changes during cortical spreading depression in the anaesthetised rat","volume":"250","author":"Read","year":"1998","journal-title":"Neurosci. Lett."},{"key":"B160","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1046\/j.1468-2982.2000.00022.x","article-title":"SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat","volume":"20","author":"Read","year":"2000","journal-title":"Cephalalgia"},{"key":"B161","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","article-title":"Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy?","volume":"186","author":"Rubio-Beltr\u00e1n","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"B162","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1146\/annurev-med-050224-111631","article-title":"CGRP and migraine: real-world insights and future therapeutic directions","volume":"77","author":"Russo","year":"2026","journal-title":"Annu. Rev. Med."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","article-title":"Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019","volume":"163","author":"Safiri","year":"2022","journal-title":"Pain"},{"key":"B164","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-025-02044-w","article-title":"The role and interaction of hypothalamic-related neurotransmitters in migraine","volume":"26","author":"Salinas-Abarca","year":"2025","journal-title":"J. Headache Pain"},{"key":"B165","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1468-2982.2004.00723.x","article-title":"LY293558, a novel AMPA\/GluR5 antagonist, is efficacious and well-tolerated in acute migraine","volume":"24","author":"Sang","year":"2004","journal-title":"Cephalalgia"},{"key":"B166","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1468-2982.2008.01566.x","article-title":"Involvement of corticotrophin-releasing factor and Orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid","volume":"28","author":"Sarchielli","year":"2008","journal-title":"Cephalalgia"},{"key":"B167","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1526-4610.2007.00970.x","article-title":"Risk factors for headache chronification","volume":"48","author":"Scher","year":"2008","journal-title":"Headache"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/brain\/aww097","article-title":"The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks","volume":"139","author":"Schulte","year":"2016","journal-title":"Brain"},{"key":"B169","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-020-01264-5","article-title":"Ubrogepant: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"B170","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00228-025-03934-3","article-title":"Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine; a network meta-analysis","volume":"82","author":"Shakir","year":"2026","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4103\/aian.AIAN_294_18","article-title":"Memantine ameliorates migraine headache","volume":"22","author":"Shanmugam","year":"2019","journal-title":"Ann. Indian Acad. Neurol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.22092\/ari.2021.356171.1797","article-title":"Clinical applications of substance P (Neurokinin-1 receptor) antagonist in canine medicine","volume":"76","author":"Sharun","year":"2021","journal-title":"Arch. Razi Inst."},{"key":"B173","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12883-025-04350-x","article-title":"The efficacy and safety of atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Shaukat","year":"2025","journal-title":"BMC Neurol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1046\/j.1468-2982.2000.00092.x","article-title":"Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453","volume":"20","author":"Smith","year":"2000","journal-title":"Cephalalgia"},{"key":"B175","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40122-025-00705-x","article-title":"Lasmiditan and different triptans in menstrual migraine: a bayesian network meta-analysis","volume":"14","author":"Song","year":"2025","journal-title":"Pain Ther."},{"key":"B176","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1523\/JNEUROSCI.4496-10.2011","article-title":"Trigeminal nociceptive transmission in migraineurs predicts migraine attacks","volume":"31","author":"Stankewitz","year":"2011","journal-title":"J. Neurosci."},{"key":"B177","doi-asserted-by":"publisher","first-page":"102784","DOI":"10.1016\/j.nicl.2021.102784","article-title":"Migraine attacks as a result of hypothalamic loss of control","volume":"32","author":"Stankewitz","year":"2021","journal-title":"Neuroimage Clin."},{"key":"B178","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/14737175.2024.2328728","article-title":"Orexins and primary headaches: an overview of the neurobiology and clinical impact","volume":"24","author":"Stanyer","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"B179","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s13311-017-0602-3","article-title":"Targeted orexin and hypothalamic neuropeptides for migraine","volume":"15","author":"Strother","year":"2018","journal-title":"Neurotherapeutics"},{"key":"B181","doi-asserted-by":"publisher","first-page":"13797","DOI":"10.3390\/ijms232213797","article-title":"PAC1, VPAC1, and VPAC2 receptor expression in rat and human trigeminal ganglia: characterization of PACAP-responsive receptor antibodies","volume":"23","author":"Tasma","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B182","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1468-2982.1993.1306395.x","article-title":"Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers","volume":"13","author":"Thomsen","year":"1993","journal-title":"Cephalalgia"},{"key":"B183","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1468-1331.1994.tb00053.x","article-title":"A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks","volume":"1","author":"Thomsen","year":"1994","journal-title":"Eur. J. Neurol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.brainres.2018.05.046","article-title":"Role of glutamate and its receptors in migraine with reference to amitriptyline and transcranial magnetic stimulation therapy","volume":"1696","author":"Tripathi","year":"2018","journal-title":"Brain Res."},{"key":"B185","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0091270008329548","article-title":"Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine?","volume":"49","author":"Van der Schueren","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-023-01611-3","article-title":"Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review","volume":"24","author":"Vandenbussche","year":"2023","journal-title":"J. Headache Pain"},{"key":"B187","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/acn3.302","article-title":"Metabotropic glutamate receptor 5: a target for migraine therapy","volume":"3","author":"Waung","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nm0795-658","article-title":"Brain stem activation in spontaneous human migraine attacks","volume":"1","author":"Weiller","year":"1995","journal-title":"Nat. Med."},{"key":"B189","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.neuropharm.2011.10.003","article-title":"Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia","volume":"62","author":"Winrow","year":"2012","journal-title":"Neuropharmacology"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1177\/0333102418791595","article-title":"Current understanding of thalamic structure and function in migraine","volume":"39","author":"Younis","year":"2019","journal-title":"Cephalalgia"},{"key":"B191","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/jcbfm.1994.125","article-title":"Cerebral blood flow changes during cortical spreading depression are not altered by inhibition of nitric oxide synthesis","volume":"14","author":"Zhang","year":"1994","journal-title":"J. Cereb. Blood Flow. Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1924544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:34:59Z","timestamp":1788950099000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1924544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":191,"alternative-id":["10.3389\/fphar.2026.1924544"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1924544","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1924544"}}